Ignite Creation Date:
2024-05-06 @ 3:44 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02355457
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2015-01-30
Brief Title:
Biomarkers in Acute Cardiac Care
Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Organization:
Universitätsklinikum Hamburg-Eppendorf
Study Overview
Official Title:
Biomarkers in Acute Cardiac Care
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BACC
Brief Summary:
The primary aim of the study is to investigate new cardiac biomarkers and algorithms to diagnose acute coronary syndrome in patients with suspected acute myocardial infarction
Detailed Description:
The primary aim of the study is to detect and evaluate new cardiac biomarkers evaluate and improve acute coronary syndrome ACS risk scores which takes into account clinical gender specific psycho-social and lifestyle-risk factors protein patterns and genetic variability in addition to the classical risk factors with respect to the primary endpoint of acute myocardial infarction
Secondary study aims are
To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain
To provide accurate quantifiable measures of precursors of ACS
DNA RNA cells and serumplasma for comprehensive genetic gene expression and proteomic studies
To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach
To explore proteins relevant for ACS
To allow the identification of new therapeutic targets
To evaluate the impact of socio-economic factors on ACS and CAD risk
Patients will be followed up during the hospital stay Afterwards a telephone follow-up will take place after 30 days 6 24 and 48 months
Secondary study aims are
To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain
To provide accurate quantifiable measures of precursors of ACS
DNA RNA cells and serumplasma for comprehensive genetic gene expression and proteomic studies
To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach
To explore proteins relevant for ACS
To allow the identification of new therapeutic targets
To evaluate the impact of socio-economic factors on ACS and CAD risk
Patients will be followed up during the hospital stay Afterwards a telephone follow-up will take place after 30 days 6 24 and 48 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None